新华制药(000756) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was CNY 1,389,149,183.41, representing a 2.69% increase year-over-year[4] - Net profit attributable to shareholders for the same period was CNY 85,253,975.87, up 15.59% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 66,051,847.57, reflecting a 6.01% increase year-over-year[4] - Basic earnings per share for Q3 2021 was CNY 0.14, an increase of 16.67% year-over-year[4] - Total operating revenue for Q3 2021 reached CNY 4,940,192,936.36, an increase of 6.5% compared to CNY 4,638,516,349.70 in the same period last year[20] - Net profit for Q3 2021 was CNY 297,252,235.38, representing a 11.2% increase from CNY 267,382,674.75 in Q3 2020[22] - Earnings per share (EPS) for Q3 2021 was CNY 0.46, compared to CNY 0.40 in the same quarter last year[22] - The company reported a total comprehensive income of CNY 249,238,018.45 for Q3 2021, compared to CNY 230,590,612.90 in Q3 2020[22] Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months was CNY 230,422,146.43, a decrease of 42.84% compared to the same period last year[7] - The net cash flow from operating activities for Q3 2021 was ¥230,422,146.43, a decrease of 42.7% compared to ¥403,088,862.25 in Q3 2020[23] - Total cash inflow from operating activities was ¥4,249,122,895.25, slightly down from ¥4,252,520,386.22 in the previous year[23] - Cash outflow for purchasing goods and services increased to ¥2,623,192,208.55 from ¥2,506,920,043.15, representing a rise of 4.6%[23] - The net cash flow from investing activities was -¥175,630,676.15, an improvement from -¥190,003,477.30 in Q3 2020[23] - Cash inflow from financing activities totaled ¥503,104,800.00, down from ¥919,500,000.00 in the same quarter last year[24] - The net cash flow from financing activities was -¥100,041,207.71, compared to a positive cash flow of ¥13,923,804.11 in Q3 2020[24] - The ending balance of cash and cash equivalents was ¥675,142,439.65, down from ¥798,135,230.21 at the end of Q3 2020[24] - The company received cash from investment income of ¥9,105,486.40, an increase from ¥8,589,271.94 in the previous year[23] - Cash paid to employees increased to ¥632,172,231.81 from ¥548,783,311.56, reflecting a rise of 15.2%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 7,189,407,562.48, a 1.36% increase from the end of the previous year[4] - The total assets of Shandong Xinhua Pharmaceutical Co., Ltd. reached approximately RMB 7.19 billion, an increase from RMB 7.09 billion in the previous period, reflecting a growth of about 1.4%[18] - The company's current assets totaled approximately RMB 2.69 billion, slightly up from RMB 2.69 billion in the previous period, indicating stable liquidity[18] - Accounts receivable increased significantly to approximately RMB 706.56 million, compared to RMB 379.91 million in the previous period, marking an increase of about 86%[17] - Inventory decreased to approximately RMB 901.66 million from RMB 1.12 billion, a decline of about 19.8%, suggesting improved inventory management[18] - Short-term borrowings rose to approximately RMB 330.36 million, up from RMB 200.42 million, indicating a 64.7% increase in leverage[18] - The total liabilities decreased to CNY 3,601,189,190.99 from CNY 3,701,662,448.12, a reduction of approximately 2.7%[20] - The total equity attributable to shareholders of the parent company increased to CNY 3,406,442,460.59 from CNY 3,223,793,819.25, marking an increase of 5.7%[20] Government Support and Strategic Initiatives - The company received government subsidies amounting to CNY 20,147,478.70 during the reporting period[6] - The company plans to expand its market presence through a non-public offering of A-shares, as approved in recent board meetings[14] - The company has adjusted the exercise price of its stock option plan from RMB 5.98 to RMB 5.76 per share, impacting the incentive structure for employees[13] - The stock option incentive plan has been revised, reducing the number of eligible participants from 185 to 184, with a total of 16.2 million options granted[13] Audit and Reporting - The company did not undergo an audit for the Q3 report[25]